Pertuzumab: Difference between revisions
No edit summary |
No edit summary |
||
| Line 56: | Line 56: | ||
The dosage of pertuzumab used in the pivotal phase III CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial was as follows: IV 840mg loading dose followed by IV 420mg q3w.<ref name="test">Keating GM. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. ''Drugs 2012 Feb 12; 72 (3): 353-60''.[http://adisonline.com/drugs/pages/articleviewer.aspx?year=2012&issue=72030&article=00005&type=abstract Link text] </ref> |
The dosage of pertuzumab used in the pivotal phase III CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial was as follows: IV 840mg loading dose followed by IV 420mg q3w.<ref name="test">Keating GM. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. ''Drugs 2012 Feb 12; 72 (3): 353-60''.[http://adisonline.com/drugs/pages/articleviewer.aspx?year=2012&issue=72030&article=00005&type=abstract Link text] </ref> |
||
The pharmacokinetics of intravenous pertuzumab appear to be unaffected by age and no drug-drug interaction has been reported with |
The pharmacokinetics of intravenous pertuzumab appear to be unaffected by age and no drug-drug interaction has been reported with docetaxel. The pharmacokinetics and pharmacodynamics of pertuzumab have recently been summarized in a review by Gillian Keating.<ref name="test">Keating GM. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. ''Drugs 2012 Feb 12; 72 (3): 353-60''.[http://adisonline.com/drugs/pages/articleviewer.aspx?year=2012&issue=72030&article=00005&type=abstract Link text] </ref> |
||
The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects in the randomized, double-blind, multinational, phase III CLEOPATRA trial.<ref name=“test”>Baselga J, Cortés J, Kim SB, and the CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. ''N Engl J Med 2012 Jan 12; 366 (2): 109-19''. [http://www.ncbi.nlm.nih.gov/pubmed/22149875 Link text] </ref> |
The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects in the randomized, double-blind, multinational, phase III CLEOPATRA trial.<ref name=“test”>Baselga J, Cortés J, Kim SB, and the CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. ''N Engl J Med 2012 Jan 12; 366 (2): 109-19''. [http://www.ncbi.nlm.nih.gov/pubmed/22149875 Link text] </ref> |
||
Revision as of 21:03, 28 March 2012
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HER2 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Pertuzumab (also called 2C4, trade name Omnitarg) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.[2] Pertuzumab is currently being developed by Genentech.
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.[3]
The dosage of pertuzumab used in the pivotal phase III CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial was as follows: IV 840mg loading dose followed by IV 420mg q3w.[4]
The pharmacokinetics of intravenous pertuzumab appear to be unaffected by age and no drug-drug interaction has been reported with docetaxel. The pharmacokinetics and pharmacodynamics of pertuzumab have recently been summarized in a review by Gillian Keating.[4]
The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects in the randomized, double-blind, multinational, phase III CLEOPATRA trial.[5]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ de Bono, Johann S.; Bellmunt, J; Attard, G; Droz, JP; Miller, K; Flechon, A; Sternberg, C; Parker, C; Zugmaier, G (20 January 2007). "Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer". Journal of Clinical Oncology. 25 (3): 257–262. doi:10.1200/JCO.2006.07.0888. PMID 17235043.
- ^ Genentech press release - May 15, 2005
- ^ a b Keating GM. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs 2012 Feb 12; 72 (3): 353-60.Link text
- ^ Baselga J, Cortés J, Kim SB, and the CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012 Jan 12; 366 (2): 109-19. Link text
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
10.1056/NEJMoa1113216